Overview of demographic and outcome features in both the training and the validation cohort
| Characteristic . | Training cohort, n (%) . | Validation cohort, n (%) . | ||||||
|---|---|---|---|---|---|---|---|---|
| All, n = 733 . | −MR, n = 369 . | +MR, n = 364 . | P . | All, n = 190 . | −MR, n = 103 . | +MR, n = 87 . | P . | |
| Sex | ||||||||
| Male | 370 (50) | 175 (47) | 195 (54) | 82 (43) | 44 (43) | 38 (44) | ||
| Female | 363 (50) | 194 (53) | 169 (46) | NS | 108 (57) | 59 (57) | 49 (56) | NS |
| Age at FL diagnosis, y | ||||||||
| Median | 61 | 61 | 62 | 61 | 62 | 60 | ||
| Range | 24-87 | 24-86 | 30-87 | NS | 21-83 | 32-83 | 21-83 | NS |
| Ann Arbor Stage | ||||||||
| I-II | 117 (16) | 82 (22) | 35 (10) | 29 (15) | 16 (15) | 13 (15) | ||
| III-IV | 611 (84) | 284 (78) | 327 (90) | <.001 | 161 (85) | 87 (85) | 74 (85) | NS |
| FLIPI | ||||||||
| Low | 114 (16) | 84 (24) | 30 (8) | 30 (16) | 12 (12) | 18 (21) | ||
| Intermediate | 173 (24) | 75 (21) | 98 (28) | 56 (29) | 31 (30) | 25 (29) | ||
| High | 424 (60) | 198(55) | 226 (64) | <.001 | 104 (55) | 60 (58) | 44 (51) | NS |
| Nodal involvement ≥4 | 524 (71) | 241 (65) | 283 (78) | <.001 | 130 (68) | 70 (68) | 60 (69) | NS |
| Bulky disease | 296 (48) | 136 (45) | 160 (51) | NS | N/A | N/A | N/A | N/A |
| B symptoms | 265 (37) | 127 (35) | 138 (38) | NS | 42 (22) | 15 (15) | 27 (31) | .008 |
| Performance score ≥2 | 32 (4) | 18 (5) | 14 (4) | NS | 29 (15) | 19 (18) | 10 (12) | NS |
| Bone marrow involvement | 323 (44) | 146 (40) | 177 (49) | .016 | N/A | N/A | N/A | N/A |
| Anemia | 143 (20) | 67 (18) | 76 (21) | NS | 27 (14) | 13 (13) | 14 (16) | NS |
| LDH elevation | 242 (34) | 120 (33) | 122 (34) | NS | 56 (30) | 32 (31) | 24 (28) | NS |
| FL histology | ||||||||
| FL NOS | 22 (3) | 7 (2) | 15 (4) | 2 (1) | 1 (1) | 1 (1) | ||
| FL grade 1-2 | 532 (73) | 255 (69) | 277 (76) | 152 (80) | 82 (80) | 70 (80) | ||
| FL grade 3A | 179 (24) | 107 (29) | 72 (20) | .005 | 36 (19)) | 20 (19) | 16 (18) | NS |
| Induction therapy | ||||||||
| R-CHOP/CHOP-like | 286 (39) | 172(47) | 114 (31) | |||||
| R-CVP/CVP-like | 347 (47) | 154 (41) | 193 (53) | 114 (60) | 50 (49) | 64 (74) | ||
| R-Benda | 69 (9) | 18 (5) | 51 (14) | 8 (4) | 2 (2) | 6 (7) | ||
| R-other chemotherapy | 31 (4) | 25 (7) | 6 (2) | <.001 | 68 (36) | 51 (49) | 17 (19) | .001 |
| Rituximab-containing induction therapy | 733 (100) | 369 (100) | 364 (100) | NS | 190 (100) | 103 (100) | 87 (100) | NS |
| Response status after induction therapy | ||||||||
| Chemosensitive (CR/PR) | 703 (97) | 345 (94) | 358 (98) | 183 (96) | 99 (96) | 84 (97) | ||
| Nonchemosensitive (NC/PD) | 19 (3) | 15 (4) | 4 (1) | 7 (4) | 11 (4) | 9 (3) | ||
| Missing | 11 (1) | 9 (2) | 2 (1) | NS | 0 | 0 | 0 | NS |
| Characteristic . | Training cohort, n (%) . | Validation cohort, n (%) . | ||||||
|---|---|---|---|---|---|---|---|---|
| All, n = 733 . | −MR, n = 369 . | +MR, n = 364 . | P . | All, n = 190 . | −MR, n = 103 . | +MR, n = 87 . | P . | |
| Sex | ||||||||
| Male | 370 (50) | 175 (47) | 195 (54) | 82 (43) | 44 (43) | 38 (44) | ||
| Female | 363 (50) | 194 (53) | 169 (46) | NS | 108 (57) | 59 (57) | 49 (56) | NS |
| Age at FL diagnosis, y | ||||||||
| Median | 61 | 61 | 62 | 61 | 62 | 60 | ||
| Range | 24-87 | 24-86 | 30-87 | NS | 21-83 | 32-83 | 21-83 | NS |
| Ann Arbor Stage | ||||||||
| I-II | 117 (16) | 82 (22) | 35 (10) | 29 (15) | 16 (15) | 13 (15) | ||
| III-IV | 611 (84) | 284 (78) | 327 (90) | <.001 | 161 (85) | 87 (85) | 74 (85) | NS |
| FLIPI | ||||||||
| Low | 114 (16) | 84 (24) | 30 (8) | 30 (16) | 12 (12) | 18 (21) | ||
| Intermediate | 173 (24) | 75 (21) | 98 (28) | 56 (29) | 31 (30) | 25 (29) | ||
| High | 424 (60) | 198(55) | 226 (64) | <.001 | 104 (55) | 60 (58) | 44 (51) | NS |
| Nodal involvement ≥4 | 524 (71) | 241 (65) | 283 (78) | <.001 | 130 (68) | 70 (68) | 60 (69) | NS |
| Bulky disease | 296 (48) | 136 (45) | 160 (51) | NS | N/A | N/A | N/A | N/A |
| B symptoms | 265 (37) | 127 (35) | 138 (38) | NS | 42 (22) | 15 (15) | 27 (31) | .008 |
| Performance score ≥2 | 32 (4) | 18 (5) | 14 (4) | NS | 29 (15) | 19 (18) | 10 (12) | NS |
| Bone marrow involvement | 323 (44) | 146 (40) | 177 (49) | .016 | N/A | N/A | N/A | N/A |
| Anemia | 143 (20) | 67 (18) | 76 (21) | NS | 27 (14) | 13 (13) | 14 (16) | NS |
| LDH elevation | 242 (34) | 120 (33) | 122 (34) | NS | 56 (30) | 32 (31) | 24 (28) | NS |
| FL histology | ||||||||
| FL NOS | 22 (3) | 7 (2) | 15 (4) | 2 (1) | 1 (1) | 1 (1) | ||
| FL grade 1-2 | 532 (73) | 255 (69) | 277 (76) | 152 (80) | 82 (80) | 70 (80) | ||
| FL grade 3A | 179 (24) | 107 (29) | 72 (20) | .005 | 36 (19)) | 20 (19) | 16 (18) | NS |
| Induction therapy | ||||||||
| R-CHOP/CHOP-like | 286 (39) | 172(47) | 114 (31) | |||||
| R-CVP/CVP-like | 347 (47) | 154 (41) | 193 (53) | 114 (60) | 50 (49) | 64 (74) | ||
| R-Benda | 69 (9) | 18 (5) | 51 (14) | 8 (4) | 2 (2) | 6 (7) | ||
| R-other chemotherapy | 31 (4) | 25 (7) | 6 (2) | <.001 | 68 (36) | 51 (49) | 17 (19) | .001 |
| Rituximab-containing induction therapy | 733 (100) | 369 (100) | 364 (100) | NS | 190 (100) | 103 (100) | 87 (100) | NS |
| Response status after induction therapy | ||||||||
| Chemosensitive (CR/PR) | 703 (97) | 345 (94) | 358 (98) | 183 (96) | 99 (96) | 84 (97) | ||
| Nonchemosensitive (NC/PD) | 19 (3) | 15 (4) | 4 (1) | 7 (4) | 11 (4) | 9 (3) | ||
| Missing | 11 (1) | 9 (2) | 2 (1) | NS | 0 | 0 | 0 | NS |
Bold values represent significant P values (P < .05).
CR, complete remission; NC, no change; NOS, not otherwise specified; NS, not significant; PD, progressive disease; PR, partial remission.